Mallinckrodt plc MNK, will have to pay a fine of $100 million to the U.S. Federal Trade Commission (FTC) to resolve the latter’s investigation into the acquisition of Synacthen Depot by its Questcor ...

Until now there has been no test that could detect synacthen, which when injected simulates the body to produce extra amounts of its own corticosteroid. This is most common in sports where sports ...

This leaflet answers some common questions about Synacthen Depot. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. All medicines ...

Injecting performance enhancing corticosteroid hormones for other than medical treatment is banned, and tests exist that can detect injected hormones. Injecting synacthen, which stimulates the body to ...

Questcor Pharmaceuticals said today it acquired rights to develop Synacthen® (tetracosactide) and Synacthen Depot in the U.S. from Novartis Pharma and parent company Novartis, in a deal that could net ...

Shares of Questcor Pharmaceuticals, Inc. (QCOR) recently received a major boost when the company announced the acquisition of development and commercialization rights to Synacthen and Synacthen Depot ...

Mallinckrodt Pharmaceuticals' agreed to pay $100 million to settle Federal Trade Commission (FTC) charges it used its monopoly on a lupus and multiple sclerosis drug, Acthar, to unfairly jack up its ...

Questcor gains rights to potential rival Synacthen. What it means for this volatile stock. What it means Questcor appears to be playing both defense and offense with this move. On the defensive front, ...

Questcor's stock leapt nearly 40% during trading yesterday as investors welcomed its $135m-plus purchase of Novartis' rival immune drug Synacthen. Questcor’s stock leapt nearly 40% during trading ...

Hormonal insufficiency of the hypothalamic–pituitary–adrenal (HPA) axis is a common complication in patients who have undergone pituitary surgery. Different procedures are used to assess HPA function ...